A 867191

Drug Profile

A 867191

Alternative Names: A867191

Latest Information Update: 24 Jan 2013

Price : $50

At a glance

  • Originator Abbott Laboratories
  • Class Antibacterials; Fluoroquinolones
  • Mechanism of Action DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 26 Mar 1998 Phase-II clinical trials for Bacterial infections in USA (Parenteral)
  • 15 Jun 1995 Three studies detailing the comparative antimicrobial activity of A 867191 have been added to the antimicrobial activity and pharmacodynamics sections ,,
  • 26 Oct 1994 Preclinical development for Bacterial infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top